Version 3 du 17 avril 2020
In vitro testing of combined Hydroxychloroquine and Azithromycin on SARS-CoV-2 shows synergistic effect
Julien Andreani, Marion Le Bideau, Isabelle Duflot, Priscilla Jardot, Clara Rolland, Manon Boxberger, Jacque Yaacoub Bou Khalil, Jean-Pierre Baudouin, Nathalie Wurtz, Jean-Marc Rolain, Philippe Colson, Bernard La Scola, Didier Raoult
Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
Lien vers l’article online : https://doi.org/10.1016/j.micpath.2020.104228